Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway

Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients

(2019) Marta Rodríguez-Balada et al.   CLINICAL BIOCHEMISTRY

Mainstreamed genetic testing for women with ovarian cancer: first-year experience

(2018) Belinda Rahman et al.   JOURNAL OF MEDICAL GENETICS

Gene panel testing of 5589 BRCA1/2 -negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer

(2018) Jan Hauke et al.   Cancer Medicine

A contemporary review of male breast cancer: current evidence and unanswered questions

(2018) Roberto A. Leon-Ferre et al.   CANCER AND METASTASIS REVIEWS

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

(2018) Sandra Bonache et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer

(2017) Martin P. Nilsson et al.   Familial Cancer

Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014

(2017) Zhuo Chen et al.   GENETICS IN MEDICINE

Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer

(2017) Allison W. Kurian et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

(2017) Karoline B. Kuchenbaecker et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer

(2017) Christopher P. Childers et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Testing: What Problem Are We Trying to Solve?

(2017) Kevin S. Hughes   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

(2016) E. T. Rodler et al.   CLINICAL CANCER RESEARCH

BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines

(2016) Danielle S. Chun et al.   Familial Cancer

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer

(2015) Daniel G. Stover et al.   BREAST

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

(2015) Hildegunn Høberg-Vetti et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals

(2015) Terri Febbraro et al.   GYNECOLOGIC ONCOLOGY

Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system

(2014) Cecelia A. Bellcross et al.   GENETICS IN MEDICINE

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis

(2014) K. Metcalfe et al.   BMJ-British Medical Journal

Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral

(2013) C. A. Bellcross et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Does the Diagnosis of Breast or Ovarian Cancer Trigger Referral to Genetic Counseling?

(2013) C. Bethan Powell et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

(2013) Shahneen K Sandhu et al.   LANCET ONCOLOGY

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk reducing mastectomy: outcomes in 10 European centres

(2008) D G R Evans et al.   JOURNAL OF MEDICAL GENETICS